Does Rallies show Form 4 insider transactions for XFOR?

Yes. Rallies tracks XFOR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is XFOR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XFOR. It does not provide personalized investment advice.

XFOR (X4 Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

X4 Pharmaceuticals, Inc. Common Stock (XFOR) is a publicly traded Healthcare sector company. As of May 21, 2026, XFOR trades at $3.82 with a market cap of $347.10M and a P/E ratio of -19.95. XFOR moved +4.12% today. Year to date, XFOR is -1.82%; over the trailing twelve months it is +39.11%. Its 52-week range spans $1.35 to $26.83. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces XFOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading XFOR stock inside the company?

Recent XFOR insider activity includes KIRSKE DAVID sold 16.96K, Craig Adam R bought 86.21K, Baldry Mark bought 1.03K, Ragan Paula sold 76.47K, and Mostafa Adam S. sold 74.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

XFOR Key Metrics

Key financial metrics for XFOR
Metric	Value
Price	$3.82
Market Cap	$347.10M
P/E Ratio	-19.95
EPS	$-0.19
Dividend Yield	0.00%
52-Week High	$26.83
52-Week Low	$1.35
Volume	25
Avg Volume	0
Revenue (TTM)	$2.56M
Net Income	$-37.45M
Gross Margin	68.83%

Recent XFOR Insider Trades

KIRSKE DAVID sold 16.96K (~$72.82K) on May 12, 2026.
Craig Adam R bought 86.21K (~$250.00K) on Oct 23, 2025.
Baldry Mark bought 1.03K (~$2.56K) on May 16, 2025.
Ragan Paula sold 76.47K (~$34.72K) on Jan 24, 2025.
Mostafa Adam S. sold 74.77K (~$33.95K) on Jan 24, 2025.

Latest XFOR News

X4 Pharmaceuticals Secures EU Approval, Eyes €226m Milestones and Full Phase 3 Enrollment — May 6, 2026
X4 Pharma Secures EU Approval for First WHIM Syndrome Therapy with €226M Milestones — Apr 29, 2026
X4 Pharmaceuticals Grants 32,000-Share Options at $4.13 Exercise Price — Apr 1, 2026
X4 Pharmaceuticals Secures EMA Opinion for WHIM Syndrome, Extends $253M Cash Runway — Mar 17, 2026
X4 Pharmaceuticals Gains Buy Rating With $12 Target and $240M Cash Raise — Mar 9, 2026

XFOR Analyst Consensus

1 analysts cover XFOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about XFOR

Who is trading XFOR stock inside the company?: Recent XFOR insider activity includes KIRSKE DAVID sold 16.96K, Craig Adam R bought 86.21K, Baldry Mark bought 1.03K, Ragan Paula sold 76.47K, and Mostafa Adam S. sold 74.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for XFOR?: Yes. Rallies tracks XFOR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is XFOR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XFOR. It does not provide personalized investment advice.